Gene therapy approach to FAP: In vivo influence of T119M in TTR deposition in a transgenic V30M mouse model (Gene Therapy advance online publication (2014) 10.1038/gt.2014.86));Gene therapy approach to FAP: In vivo influence of T119M in TTR deposition in a transgenic V30M mouse model

Gene Therapy

Volumn 21, Issue 12, 2014, Pages 1041-1050

  Batista, A R ^a,b   Gianni, D ^c   Ventosa, M ^d   Coelho, A V ^d   Almeida, M R ^a,b   Sena Esteves, M ^c   Saraiva, M J ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ERROR; PRIORITY JOURNAL; AMYLOID NEUROPATHIES, FAMILIAL; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC MARKER; GENETICS; LIVER; METABOLISM; MOUSE; PERIPHERAL NERVOUS SYSTEM; PROCEDURES; PROTEOMICS; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

GELATINASE B; GENETIC MARKER; MMP9 PROTEIN, MOUSE; PREALBUMIN; SCLEROPROTEIN;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC MARKERS; GENETIC THERAPY; GENETIC VECTORS; LIVER; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; PERIPHERAL NERVOUS SYSTEM; PREALBUMIN; PROTEOMICS;

EID: 84927178650     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.111     Document Type: Erratum

References (48)

1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427
2. Raz A, Goodman DS. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 1969; 244: 3230-3237
3. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR., et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73-85
4. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001; 276: 27207-27213
5. Adams D, Theaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 2014; 14: 435
6. Ando Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 2005; 38: 142-154
7. Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012; 19: 2312-2323
8. Alves IL, Altland K, Almeida MR, Winter P, Saraiva MJ. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat 1997; 9: 226-233
9. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P., et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-792
10. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-2667
11. Coelho T, Chorão R, Sousa A, Alves I, Torres MF, Saraiva MJM. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul Disord 1996; 6: S20
12. Alves IL, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30] transthyretin and [Met119]transthyretin. Eur J Biochem 1997; 249: 662-668
13. Sebastiao MP, Lamzin V, Saraiva MJ, Damas AM. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol 2001; 306: 733-744
14. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293: 2459-2462
15. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713-716
16. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-593
17. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224
18. Mingozzi F, Liu Y-L, Dobrzynski E, Kaufhold A, Liu JH, Wang Y., et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356
19. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004; 50: 1748-1754
20. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007; 8: 597-608
21. Malentacchi F, Forni G, Vinci S, Orlando C. Quantitative evaluation of DNA methylation by optimization of a differential-high resolution melt analysis protocol. Nucleic Acids Res 2009; 37: e86
22. Alves IL, Divino CM, Schussler GC, Altland K, Almeida MR, Palha JA., et al. Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab 1993; 77: 484-488
23. Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ. Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 1997; 6: 309-315
24. Altland K, Rauh S, Hackler R. Demonstation of human prealbumin by double one-dimensional slab gel electrophoresis. Electrophoresis 1981; 2: 148-155
25. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimarães A, Saraiva MJ. Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 2006; 97: 151-161
26. Kohno K, Palha JA, Miyakawa K, Saraiva MJ, Ito S, Mabuchi T., et al. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 1997; 150: 1497-1508
27. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001; 159: 1993-2000
28. Sousa MM, do Amaral JB, Guimarães A, Saraiva MJ. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 2005; 19: 124-126
29. Teixeira PF, Cerca F, Santos SD, Saraiva MJ. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006; 281: 21998-22003
30. Macedo B, Batista AR, do Amaral JB, Saraiva MJ. Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Mol Med 2007; 13: 584-591
31. Cardoso I, Brito M, Saraiva MJ. Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related. Dis Markers 2008; 25: 37-47
32. Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S., et al. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Therapy 2004; 11: 838-846
33. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD., et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609-618
34. Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW., et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 2010; 17: 43-49
35. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-829
36. Kamata M, Susanto MT, Chen ISY. Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells. J Gene Med 2009; 11: 103-111
37. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-10226
38. Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006; 119: 571-603
39. Mccarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Therapy 2003; 10: 2112-2118
40. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y., et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888
41. Nathwani AC, Cochrane M, McIntosh J, Ng CY, Zhou J, Gray JT., et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Therapy 2009; 16: 60-69
42. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J., et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328
43. Broekman ML, Baek RC, Comer LA, Fernandez JL, Seyfried TN, Sena-Esteves M. Complete correction of enzymatic deficiency and neurochemistry in the GM1- gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol Ther 2007; 15: 30-37
44. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN., et al. Self-complementary adeno-associated virus vectors containing a novel liverspecific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653-2661
45. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006; 138: 501-510
46. Cardoso I, Almeida MR, Ferreira N, Arsequell G, Valencia G, Saraiva MJ. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem J 2007; 408: 131-138
47. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622
48. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G., et al. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 2004; 381: 351-356